Based on the Phase I result, IntraBiotics in November 2000 began patient enrollment in a Phase IIa clinical trial of Protegrin
IB-367, designed to evaluate the safety and efficacy of Protegrin
IB-367 when administered for several days.
today announced the successful completion of the company's Phase II clinical study of Protegrin
IB-367 Rinse for the prevention and treatment of oral mucositis, a severely debilitating ulcerative condition resulting from tissue damage caused by cancer therapies.
announced today the reacquisition of global rights to Protegrin
IB-367, a topical antimicrobial, from Pharmacia & Upjohn, S.
SFM075 01/15/2001 15:05 r f bc-CA-IntraBiotics-webca (MOUNTAIN VIEW) IntraBiotics Announces Conference Call and Web Cast to Discuss Phase III Clinical Trials of Protegrin
Her knowledge of the pharmaceutical business development arena brings an immediate contribution to our efforts to partner one of our product candidates, Protegrin
IB-367 Aerosol for the treatment of respiratory infections.
FDA Grants Fast-Track Status for Protegrin
Kelley indicated that the funds raised would primarily be used to further the Phase II clinical trials currently in progress for three potential new antibiotic products based on two novel technologies, Ramoplanin and Protegrin
announced today that it had begun a Phase I clinical trial of Protegrin
IB-367 Aerosol, a potential new antibiotic treatment for respiratory infections.
announced today that it had begun a Phase II clinical trial of Protegrin
IB-367, a potential new treatment for oral mucositis, a severely debilitating ulcerative condition resulting from tissue damage caused by cancer therapies and invasion of that tissue by microorganisms.
today announced that the United States Patent and Trademark Office had issued to The University of California, Los Angeles (UCLA) a patent, Number 5,804,558, covering the protegrin
technology exclusively licensed by IntraBiotics for use as an antimicrobial agent.
Nasdaq: IBPI), a biopharmaceutical company engaged in the development of novel antibiotics, today said that data from recently completed Phase I clinical trials in patients with cystic fibrosis (CF) support further study of IntraBiotics' Protegrin
IB-367 aerosol for the treatment of respiratory infections associated with CF.
today announced positive results of a Phase I human clinical trial of Protegrin
IB-367, a potential new treatment for oral mucositis, a severely debilitating ulcerative condition resulting from tissue damage caused by cancer therapies and microorganisms invading the tissue.